It seems that every day, from the New York Times to the Washington Post, new headlines are excitedly announcing the therapeutic benefits of psychedelics. Indeed, there is no shortage of groundbreaking clinical trials taking place that are revealing the powerful therapeutic properties these compounds have today. Coverage of the psychedelic renaissance in mainstream media outlets has skyrocketed in recent months. From the slew of new companies going public in the space to the riveting clinical trial data, psychedelic stories are being splashed across the front pages of the biggest publications in the world. This guide will explore this recent trend in the media and what this means for the psychedelic medicine movement.
Psychedelics Are Making a Comeback in Mainstream Media Coverage
Going into 2021, it seemed coverage into psychedelic medicine was taking a backseat to coverage of the COVID-19 pandemic. However, as the pandemic began exposing serious cracks in our approach to global mental healthcare, the promise of psychedelics quickly became a relevant and popular story. From their ability to radically treat treatment-resistant depression to addiction, PTSD, and more, the world needs psychedelic medicine more now than ever before. With the pandemic taking a serious toll on the global mental health of billions and the need for better interventions at an all-time high, it seems the media is embracing the promise that is psychedelic medicine. From capital markets to the conditions they treat, the mainstream media is diving deep into all aspects of modern psychedelic culture. Here’s a broad snapshot of some recent stories in some of the world’s leading publications.
All The Major Mainstream Media Outlets Reported on MAPS’ Phase 3 MDMA Trials
In a landmark moment for psychedelic medicine, the Multidisciplinary Association for Psychedelic Studies (MAPS) recently published their Phase 3 clinical trial data from their MDMA trials in Nature Medicine and reported powerfully promising results. The impressive data showed that after 18 weeks and three MDMA-assisted psychotherapy sessions, 67% of participants no longer met the criteria for a PTSD diagnosis. From Yahoo News and ABC to Time Magazine, the New York Times, our newsroom at Microdose, and beyond, all the major outlets splashed huge headlines about MDMA’s success across their websites and front pages. Indeed, the news marks a massive milestone in psychedelic medicine and suggests that the psychedelic renaissance is indeed just getting underway.
Rolling Stones Runs Riveting Piece On Psychedelics & Addiction Treatment
A recent piece in Rolling Stone titled “How a Psychedelic 12-Step Program is Saving Lives” fascinatingly explored the story of a former heroin addict, Dimitri, and how the juxtaposition of psychedelic healing and the 12-step program gave birth to a new kind of psychedelic 12-step program. With the opioid epidemic raging on in the wake of this pandemic, more people are turning to Ibogaine, a psychedelic shrub from Africa that can interrupt addiction and eliminate opioid withdrawal. This interesting piece in Rolling Stone explores how a new group attempting to incorporate psychedelic healing into the twelve-step program, despite the “total abstinence” foundation AA and NA is built on.
The move is courageous and indeed controversial given the firm belief in “total abstinence” from all drugs and alcohol, including psychedelic drugs, most traditional members of the group hold. Nevertheless, this fascinating piece helps bring to light the efforts of a courageous new group of people fighting addiction and trying to help their fellow addicts fight theirs. For those following the psychedelic renaissance, this is one piece you’ll want to check out.
Major Financial Outlets Are Covering the Economics of Psychedelic Medicine
While the wildly transformational benefits offered by psychedelic drugs certainly make for a great story, it turns out the economics of psychedelic medicine do too. Some of Wall Street’s biggest investors are making headlines with their positive predictions and bullish forecasts about psychedelics. Just recently, CNBC published an article titled “‘Shark Tank host Kevin O’Leary: Psychedelic drugs ‘far exceed’ cannabis investment potential” where the renowned investor talks about his investments in MindMed stock and Compass Pathways stock, two major public players in the space.
Indeed, with countless new investors entering the space every day, the demand for quality financial media in this space is only growing. From Bloomberg to Business Insider and beyond, all the major financial publications are eagerly covering the modern renaissance and the economics associated with it.
Want to learn more about the current state of financial media in psychedelics? Check out this PsyCap Special Report and be sure to catch the Financial Media content panel at the upcoming Psychedelic Capital conference on May 31st. You can grab your tickets here!
New Psychedelics Coverage in the Mainstream Media is Appearing Every Couple of Days
Ever since the prestigious New England Journal of Medicine reported renowned researcher Robin Carhart-Harris found psilocybin to be 4x more effective than SSRIs, psychedelics coverage has exploded. Over 17 stories have appeared in mainstream media articles since then, that come out to a new story every couple of days! From NBC, The Guardian, and Forbes to The Telegraph, several in the New York Times, and more, psychedelics are dominating the news. With the increase in coverage of such a clinically focused area of medicine, the need for accurate reporting is growing as well. It will certainly be fascinating to see how the different media outlets maneuver the covering of this rapidly emerging field and the greater phenomenon that is psychedelic medicine’s reintegration into the mainstream.
For up-to-date objective and accurate coverage of the psychedelic renaissance and all the psychedelic science that goes along with it, stay tuned to the evidence-based reporting at Microdose. You can subscribe to the Monthly Microdose email newsletter for all the latest info on conferences, content, and more by clicking here.
It seems that every day, from the New York Times to the Washington Post, new headlines are excitedly announcing the therapeutic benefits of psychedelics. Indeed, there is no shortage of groundbreaking clinical trials taking place that are revealing the powerful therapeutic properties these compounds have today. Coverage of the psychedelic renaissance in mainstream media outlets has skyrocketed in recent months. From the slew of new companies going public in the space to the riveting clinical trial data, psychedelic stories are being splashed across the front pages of the biggest publications in the world. This guide will explore this recent trend in the media and what this means for the psychedelic medicine movement.
Psychedelics Are Making a Comeback in Mainstream Media Coverage
Going into 2021, it seemed coverage into psychedelic medicine was taking a backseat to coverage of the COVID-19 pandemic. However, as the pandemic began exposing serious cracks in our approach to global mental healthcare, the promise of psychedelics quickly became a relevant and popular story. From their ability to radically treat treatment-resistant depression to addiction, PTSD, and more, the world needs psychedelic medicine more now than ever before. With the pandemic taking a serious toll on the global mental health of billions and the need for better interventions at an all-time high, it seems the media is embracing the promise that is psychedelic medicine. From capital markets to the conditions they treat, the mainstream media is diving deep into all aspects of modern psychedelic culture. Here’s a broad snapshot of some recent stories in some of the world’s leading publications.
All The Major Mainstream Media Outlets Reported on MAPS’ Phase 3 MDMA Trials
In a landmark moment for psychedelic medicine, the Multidisciplinary Association for Psychedelic Studies (MAPS) recently published their Phase 3 clinical trial data from their MDMA trials in Nature Medicine and reported powerfully promising results. The impressive data showed that after 18 weeks and three MDMA-assisted psychotherapy sessions, 67% of participants no longer met the criteria for a PTSD diagnosis. From Yahoo News and ABC to Time Magazine, the New York Times, our newsroom at Microdose, and beyond, all the major outlets splashed huge headlines about MDMA’s success across their websites and front pages. Indeed, the news marks a massive milestone in psychedelic medicine and suggests that the psychedelic renaissance is indeed just getting underway.
Rolling Stones Runs Riveting Piece On Psychedelics & Addiction Treatment
A recent piece in Rolling Stone titled “How a Psychedelic 12-Step Program is Saving Lives” fascinatingly explored the story of a former heroin addict, Dimitri, and how the juxtaposition of psychedelic healing and the 12-step program gave birth to a new kind of psychedelic 12-step program. With the opioid epidemic raging on in the wake of this pandemic, more people are turning to Ibogaine, a psychedelic shrub from Africa that can interrupt addiction and eliminate opioid withdrawal. This interesting piece in Rolling Stone explores how a new group attempting to incorporate psychedelic healing into the twelve-step program, despite the “total abstinence” foundation AA and NA is built on.
The move is courageous and indeed controversial given the firm belief in “total abstinence” from all drugs and alcohol, including psychedelic drugs, most traditional members of the group hold. Nevertheless, this fascinating piece helps bring to light the efforts of a courageous new group of people fighting addiction and trying to help their fellow addicts fight theirs. For those following the psychedelic renaissance, this is one piece you’ll want to check out.
Major Financial Outlets Are Covering the Economics of Psychedelic Medicine
While the wildly transformational benefits offered by psychedelic drugs certainly make for a great story, it turns out the economics of psychedelic medicine do too. Some of Wall Street’s biggest investors are making headlines with their positive predictions and bullish forecasts about psychedelics. Just recently, CNBC published an article titled “‘Shark Tank host Kevin O’Leary: Psychedelic drugs ‘far exceed’ cannabis investment potential” where the renowned investor talks about his investments in MindMed stock and Compass Pathways stock, two major public players in the space.
Indeed, with countless new investors entering the space every day, the demand for quality financial media in this space is only growing. From Bloomberg to Business Insider and beyond, all the major financial publications are eagerly covering the modern renaissance and the economics associated with it.
Want to learn more about the current state of financial media in psychedelics? Check out this PsyCap Special Report and be sure to catch the Financial Media content panel at the upcoming Psychedelic Capital conference on May 31st. You can grab your tickets here!
New Psychedelics Coverage in the Mainstream Media is Appearing Every Couple of Days
Ever since the prestigious New England Journal of Medicine reported renowned researcher Robin Carhart-Harris found psilocybin to be 4x more effective than SSRIs, psychedelics coverage has exploded. Over 17 stories have appeared in mainstream media articles since then, that come out to a new story every couple of days! From NBC, The Guardian, and Forbes to The Telegraph, several in the New York Times, and more, psychedelics are dominating the news. With the increase in coverage of such a clinically focused area of medicine, the need for accurate reporting is growing as well. It will certainly be fascinating to see how the different media outlets maneuver the covering of this rapidly emerging field and the greater phenomenon that is psychedelic medicine’s reintegration into the mainstream.
For up-to-date objective and accurate coverage of the psychedelic renaissance and all the psychedelic science that goes along with it, stay tuned to the evidence-based reporting at Microdose. You can subscribe to the Monthly Microdose email newsletter for all the latest info on conferences, content, and more by clicking here.